Vineet Laboratories DuPont analysis

Per cent unless marked ×
Tap a line for its trendLast 12Mto Jun 2026FY26Mar 2026FY25Mar 2025FY24Mar 2024FY23Mar 2023FY22 and earlierAlpha Plus
5-step DuPont — ROE = tax burden × interest burden × EBIT margin × turnover × leverage
FY22 and earlierEvery year the company has filed comes with Alpha Plus.
1.34×1.25×0.97×2.83×0.62×
0.37×0.21×1.11×0.08×0.38×
12.9%10.2%−25.0%3.1%2.5%
0.54×0.54×0.71×1.29×1.83×
2.74×2.74×6.45×3.37×3.44×
9.4%4.0%−123.4%3.0%3.7%
5.3%5.3%−81.8%3.0%3.7%
Open the chart

From the company's filings with NSE and BSE (Ind-AS), standalone. For information only, not investment advice.

VINEETLAB₹37.76

Vineet Laboratories Limited

· Pharma & Health
₹ CrorePeersBIOFILCHEMMANGALAMLASAKREBSBIOALPABALPHARMAORTINGLOBENATCAPSUQMcap ₹72.5 Cr
ProfitabilityGrowthCreditLiquidityWorking CapitalYield AnalysisDuPont
Ratios — % unless marked ×
12 Months Ending
FY23
31/03/2023
FY24
31/03/2024
FY25
31/03/2025
FY26
31/03/2026
Last 12M
30/06/2026
5-Step DuPont — ROE = Tax Burden × Interest Burden × EBIT Margin × Turnover × Leverage
Tax Burden (Net Income/Pretax) ×0.622.830.971.251.34
Interest Burden (Pretax/EBIT) ×0.380.081.110.210.37
EBIT Margin %2.493.11-25.0510.2112.86
Asset Turnover ×1.831.290.710.540.54
Financial Leverage (Assets/Equity) ×3.443.376.452.742.74
ROE (5-step product, year-end total equity) %3.712.96-123.383.999.44
ROE (owners' profit / average owners' equity) %3.723.00-81.795.325.32
No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY26 · StandaloneFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.